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Background: When availability and/or affordability of anti-hemophilic factor concentrates are limited, optimal
prophylaxis regimens in severe hemophilia A (HA) remain to be determined. In selected situations, low-dose
daily prophylaxis (LDDP) may be an effective and economical option. The goal of our study was to evaluate
if subjects on a LDDP regimen could achieve adherence and good clinical outcome.
Methods: Seventeen subjects (age between 15.2 and 28.4) on LDDP suffering from severe/moderate HA were
followed prospectively for 2 to 3 years as part of a health-related quality of life (HRQoL) study. Bleeding and
treatments data were collected using electronic diaries and validated every three months. The SF-36 questionnaire
was administered at the beginning of the study and then every 6 months until the end of the study.
Results: The subjects (mean age 22.0, median 21.9, standard deviation 4.06), were all from a single centre
and on LDDP for at least 12 months as part of their routine care before entering the study. Fifteen subjects
were prescribed a daily dose of 500 IU factor VIII (FVIII) and 2 subjects received 1000 IU FVIII per day,
resulting into a median dose of 7.1 IU/kg/day (ranging from 4 to 13 IU/kg/day) and of 2591 IU/kg/year.
Median adherence (the percentage of the prescribed daily dose received) was 84 % (mean 80 %, range 57 %
to 94 %) throughout the study. Seventy-six bleeds in the 6 index joints and 51 other types of bleeds were
observed throughout the study. The median annualized bleeding rate in joints (ABRjoints) was 0.7 and the
median annualized bleeding rate for all bleeds (ABRall) was 1.6. The Physical Component and Mental Component
Summary scores of SF-36, and the Hemophilia Joint Health Score were not significantly different over the course of
the study (respective medians of 49.8, 52.4 and 16.0 at entry; vs. 52.5, 51.5 and 16.0 upon exit).
Conclusions: This prospective longitudinal study in youth and young adults shows that LDDP may be associated
with low ABRs, adequate adherence and HRQoL comparable to previously reported.
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Hemophilia A (HA) is an inherited X-linked bleeding
disorder leading to recurrent joint bleeding and chronic
arthropathy, if untreated. Prophylaxis (i.e. regular, long-
term anti-hemophilic factor replacement) is recommended
as a standard of care by organizations such as the World
Federation of Hemophilia, for treating severe hemophilia
[1]. Based on reports of the 25-year Swedish experience [2],
3-times-weekly prophylaxis was established in the 90’s as
the standard, to help maintain adequate plasma factor VIII
(FVIII) trough levels (>0.01 IU/mL), and prevent spontan-
eous joint bleeding in severe HA. However, breakthrough
bleeding still occurs in certain subjects with severe HA,
despite standard thrice-weekly prophylactic doses, perhaps
due to variations in FVIII trough levels. Based on pharma-
cokinetic principles, more frequent infusions of FVIII at
lower doses may result in comparable or improved trough
levels [3, 4]. A 2012 pilot study demonstrated that daily
prophylaxis is feasible, with a substantial reduction (30 %)
in factor concentrate utilization - albeit with a higher
bleed rate in certain patients, and a decreased quality
of life [5]. Verma et al. recently demonstrated that a
very low dose, twice-weekly prophylaxis regimen in chil-
dren was effective at lowering bleed rates compared to
on-demand treatment [6].
The present study describes clinical outcomes, health-
related quality of life (HRQoL) and adherence to treat-
ment in a cohort of youth and young adults with severe
HA from a single centre, followed for 2 to 3 years on
a Low-Dose Daily Prophylaxis (LDDP) regimen. This
cohort was part of a larger, prospective and longitudinal
study of HRQoL in Canada, the Canadian Helixate Qua-
lity of Life Study (CHeQoLS).
Methods
CHeQoLS was a prospective non-interventional study
describing longitudinal HRQoL in 48 youth and young
adults with moderate or severe HA [7], conducted over
three years in 6 Canadian Hemophilia Treatment
Centres (HTCs). Male subjects 14 to 29 years of age were
eligible for CHeQoLS if they had moderate (FVIII level
0.02 – 0.05 U/ml) or severe HA (FVIII level <0.02 U/ml)
and were using the antihemophilic factor concentrate
Helixate FS® (CSL Behring, King of Prussia, PA, USA) as
a prophylactic or on-demand treatment. Exclusion criteria
were presence of a current inhibitor to FVIII (defined
as ≥ 0.6 Bethesda Units/mL), human immunodeficiency
virus (HIV) or symptomatic hepatitis C virus (HCV) infec-
tion [7]. CHeQoLS was funded by CSL Behring Canada
and was registered in Clinical Trials.gov under the registry
number NCT01034904 on December 17, 2009.
One of the 6 CHeQoLS study sites, CHU Sainte-
Justine in Montreal, had introduced LDDP as an alterna-
tive treatment regimen in 1998, in an effort to reducefrequency of hemarthroses in patients who manifested
breakthrough bleeds, while on standard 3-times-weekly
FVIII prophylaxis. This regimen was well tolerated and
became the regular or routine treatment regimen for
many patients at this HTC, irrespective of the presence
of breakthrough bleeding. None of the other CHeQoLS
participating sites had patients on LDDP.
The current study is a secondary analysis of all 17
subjects participating in the CHeQoLS who were specifi-
cally from CHU Saint-Justine, and who were on a LDDP
regimen as part of their routine care when they were
recruited in CHeQoLS. This secondary analysis is in line
with the original intent of the CHeQoLS study and its
scope was included in the written informed consent pro-
vided by all subjects prior to enrollment. The consent
procedure is described below in the Declarations section.
Permission to conduct this analysis was granted by the
owners of the data.
A medical history was obtained at baseline (including
hemophilia severity, current treatment, concomitant
medical conditions, target joint history in the year prior
to enrollment and history of previous surgeries and major
bleeding events) as well as a comprehensive demographic
survey in relation to educational and professional ex-
perience. Bleeding and treatment logs were recorded
by subjects using the HeliTrax® (CSL Behring, King of
Prussia, PA, USA) electronic diary, and later reviewed
and validated on a quarterly basis by the study nurse.
A physical examination, including joint assessment using
the Hemophilia Joint Health Score (HJHS) 2.0 [8] was per-
formed by the study physiotherapist at baseline and yearly
while on study. The HJHS assesses 6 key joints (elbows,
knees and ankles) for swelling, muscle atrophy, strength,
crepitus, range of motion, pain and gait, resulting in a
total score ranging from 0 to 124 – where the absence of
abnormal findings corresponds to a score of 0.
Annualized bleeding rate for all bleeds (ABRall) and
for joint bleeds (ABRjoints) were calculated based on
electronic diary records obtained with HeliTrax® by com-
puting the absolute number of bleeds for each successive
12 month period of observation. Adherence to treatment
was expressed as a percentage, calculated by dividing the
number of prophylactic infusions administered (based
on electronic diary records) by the number of infusions
prescribed over a given period of time.
A generic HRQoL questionnaire widely used in hemo
philia, the Medical Outcomes Study 36-Item Short Form
(SF-36v2), was completed at baseline and every six
months by all study subjects. SF-36v2 consists of 36
questions from which scores are computed in 8 domains
that can be summarized in 2 summary scores: the
Physical Component Summary (PCS) and the Mental
Component Summary (MCS) scores. These summary
scores are norm-referenced, with an expected mean











Type of hemophilia 16 severe
1 moderate
≥1 Target Joint 24 %
Daily factor concentrate dose 500 IU daily = 15
1000 IU daily = 2
Education 17.6 % college level
17.6 % secondary level
11.8 % university level
53.0 % other/unknown
Occupation 47 % students
35.3 % high physical demanding
occupation
11.8 % low physical demanding
occupation
5.9 % other/unknown
Mizrahi et al. BMC Hematology  (2016) 16:26 Page 3 of 6of 50 and a standard deviation of 10 points in a normal
population [9].
The data collected were analysed primarily using de-
scriptive statistics. Parametric statistics were used for
normally distributed variables, and non-parametric sta-
tistics were presented for data whose distribution was
non-normal. A paired-sample t-test (two-tailed) was
used to compare HRQoL scores at study entry and exit.
Results
During CHeQoLS recruitment, 39 potential subjects
aged 14 to 29 years with moderate or severe HA were
registered at the CHU Sainte-Justine HTC. Fourteen
subjects were excluded because they did not provide
consent or meet all inclusion criteria, received treat-
ments other than Helixate FS®, or were unable to comply
with data collection (electronic diary) or to fill question-
naires in French/English. Of the 25 CHU Sainte-Justine
subjects recruited into CHeQoLS, 17 subjects (mean age
22.0, median 21.9, standard deviation 4.06) were on
LDDP and are included in this study. All subjects had
severe/moderate HA, had been on LDDP at least a year
prior to recruitment and remained on a LDDP regimen
throughout the study. Other characteristics of study
subjects are summarized in Table 1.
The prescribed dose for LDDP was 500 IU per day
in 15 cases and 1000 IU per day in 2 cases. This
translated into a median daily dose of 7.1 IU/kg/day
(range 4–13 IU/kg/day), equivalent to 2591 IU/kg/
year (range 1460–4745 IU/kg/year). Adherence of individ-
ual subjects to their LDDP regimens ranged from 56 % to
98 % (median 85 %, mean 81 %) over their entire obser-
vation period. Adherence rates remained relatively stable
for the cohort throughout the course of observation,
ranging from 58 % to 99 % (median 88 %, mean 82 %)
during the first three months of observation, to 48 % to
100 % (median 80 %, mean 77 %) during the last three
months of the study.
Over the 516 subject-months of cumulative observa-
tion, there were 76 hemarthroses in the 6 index joints
and 51 other types of bleeds. The median ABRjoints and
ABRall values were respectively 0.7 (range 0.0–9.6) and
1.6 (range 0.0–11.8) (Table 2). The median HJHS was 16
(range 0–34) at study entry, and remained unchanged
upon exit (median 16, range 0-38) (Table 3). The mean
PCS and MCS scores of the SF-36v2 respectively were
49.1 (SD = 5.65) and 51.0 (SD = 7.83) at study entry, vs.
51.8 (SD = 5.92) and 47.9 (SD = 9.45) upon study exit
(Table 3). The minimally important difference (MID)
threshold for the SF-36v2 was used as the criterion for
clinical significance [9]. The minimally clinically relevant
differences are respectively defined as 3 and 2 for PCS
and MCS scores [9]. The differences between the scores
at entry and exit approached the MID, but were notstatistically significant (PCS t = –1.68, P = 0.113; MSC
t = 1.75; P = 0.099).
Discussion
Primary prophylaxis is considered to be the gold stand-
ard for preserving joint function in severe HA. This rec-
ommendation is supported by many studies, notably the
Manco-Johnson et al. randomized and controlled trial,
comparing on-demand therapy to full-dose prophylaxis
[10, 11]. Secondary prophylaxis in children, adolescents
and adults with HA has also been shown to be beneficial
for joint protection [12–17]. In addition, prophylaxis
prevents bleeding and reduces the risk of life-threatening
hemorrhages [10, 11, 18]. The purpose of our study
was to describe clinical outcomes (bleeding rates and
joint health), adherence to treatment and HRQoL in a
cohort of patients treated on a LDDP regimen, while
participating in a non-interventional and longitudinal
study of youth and young adults with moderate or
severe HA in Canada [7].
In our study, LDDP resulted in a median ABRall of 1.6
and a median ABRjoints of 0.7 with a tendency towards
a reduction in bleeding between the first year and the
Table 2 Summary of Annual Bleeding Rates (ABRs) for index joints (ABRjoints) and all bleeds (ABRall) in 17 male subjects with
severe/moderate HA on a LDDP regimen
Annualized bleeding rates in joints (ABRjoints) Annualized bleeding rates for all bleeds (ABRall)
Year 1 Year 2 Year 3 Average of 3 years Year 1 Year 2 Year 3 Average of 3 years
Median 1.10 1.00 0.00 0.70 2.00 2.00 0.90 1.63
Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Maximum 11.50 9.20 8.00 9.57 11.50 13.80 10.00 11.77
Standard Deviation 2.68 2.47 2.81 2.65 3.57 3.34 3.67 3.53
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health status as evaluated by the HJHS (Table 3). Our
ABRs are similar to what has previously been described
in the literature [11, 14]. Valentino et al. compared
the efficacy of two prophylactic regimens (standard
20–40 IU/kg every other day, or pharmacokinetic-
tailored 20-80 IU/kg every third day) to on-demand
treatment in 7- to 59-year-old male subjects. ABRall
in both prophylactic regimens were comparable and
statistically less than on-demand therapy (respectively
1.0, 2.0 and 43.9 for standard, pharmacokinetic-tailored
prophylaxis and on-demand therapy). In addition, median
ABRjoints was higher for on-demand treatment than
prophylactic treatments (38.3 vs 1.0) reflecting the benefits
of long-term prophylaxis [11].
Discontinuation or inadequacy of prophylaxis can
result in increased bleeding episodes and/or worsening of
target joint status [18–20]. Non-adherence and interfe-
rence with lifestyle are considered the main causes for
discontinuing prophylaxis [18], while prophylaxis efficacy
may be compromised by previous joint damage or un-
favourable pharmacokinetics [21]. Our results showed
adequate overall adherence throughout the study duration
(median 85 %, mean 81 %), with little difference between
the first three months vs. last three months of the study
(respectively median 88 %, mean 82 %, vs. median 80 %,
mean 77 %). Previous studies have reported average
prophylaxis adherence in severe hemophilia A or B ofTable 3 Description of SF-36v2 and HJHS scores upon study









Median 49.8 52.5 52.4 51.5 16.0 16.0
Minimum 40.0 40.7 33.6 32.6 0.0 0.0
Maximum 59.2 61.0 63.0 62.2 34.0 38.0
Mean 49.1 51.8 51.0 47.9 14.4 13.9
Standard
Deviation
5.66 5.92 7.83 9.45 8.54 8.98
t-test -1.68 1.75 0.45
P value 0.11 0.10 0.66between 58.8 % and 87 % [22, 23]. In a study of 31 adults
patients with severe hemophilia A or B, Ho et al. [24] re-
ported adherence to a prescribed prophylaxis frequency (3
times per week) and dosage (2000 UI/dose) to be
respectively, 76 % and 93 % on a 78-week period, which
was similar to our results. Moreover adherence is posi-
tively correlated with younger age and longer exposure to
prophylaxis [23, 24], a finding also illustrated in our study,
as patients were on a LDDP regimen for at least a year
before enrollment.
Long-term prophylaxis in severe HA can however be
limited by cost issues. Fischer et al. reported a 66 %
higher total cost in high-dose vs. intermediate-dose
prophylaxis in children and adults, due to a higher FVIII
consumption (4000 IU/kg/year vs 2100 IU/kg/year)
[25]. Unsurprisingly, Valentino et al. observed a lower
median annualized consumption for on-demand treat-
ment compared to prophylaxis, respectively 2152.2 and
5733.3 IU/kg per year [11]. Interestingly, in our cohort,
the LDDP regimen also resulted in a lower median FVIII
consumption compared to 2 previous reports for standard
prophylactic regimens (2591 IU/kg/year in our study
compared to 3223-4082 IU/kg/year in respectively ≥19
and 13-18 year old subjects [26]; 3664.5–3795.8 IU/kg/
year in respectively 12-25 and 26–55 year old subjects
[14]). Crivaniu-Gaita et al. also found once-a-day prophy-
laxis was associated with a 23.5 % decreased FVIII con-
sumption in youth and young adults with severe HA,
compared to standard prophylactic regimens [27]. A rela-
tively lower annual consumption of FVIII concentrate
associated with LDDP may reduce the annual cost per
patient if not associated with increased bleeding.
Given the chronicity, potential chronic morbidity
and the burden of treatment in severe HA, HRQoL
becomes a valuable assessment outcome in this popu-
lation. Although certain disease-specific tools have been
established to measure HRQoL in hemophilia [28], the
generic instrument SF-36 has been widely used in HA.
SF-36 also allows comparison with normal population or
with groups with other diagnoses. In our cohort, the PCS
and MCS summary scores of SF-36v2 varied minimally
from baseline to the end of study and were similar to
those reported at baseline in the larger CHeQoLS study
(mean PCS 51.7 ± 6.5, mean MCS 51.1 ± 8.6) [7]. This low
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were already on a LDDP regimen at study entry, but also
by the low number of subjects enrolled in our study. In
the Advate PASS study, Klamroth et al. assessed HRQoL
in HA patients compared to healthy subjects, and to
populations with other chronic diseases [29]. In their
study, the PCS was reduced in HA (42.3 ± 0.77) compared
to age-matched healthy subjects (54.5 ± 0.24) or those
with chronic back pain (46.9 ± 0.4), but comparable to
subjects with rheumatoid arthritis (43.6 ± 1.89). Age was
an important factor across all populations, as the PCS
generally decreased over the years. In our study, mean
MCS was unchanged at the end of the study (51.5 ± 9.45
compared to 52.4 ± 7.83) but still higher than the US
general norms (47.7 ± 0.24) reported by Klamroth et al.
[29], whereas mean PCS was comparable to baseline
(52.5 vs 49.8) and US general norms (50.7 ± 0.23).
The major limitations of our study are a result of our
small sample of subjects, all of whom were from a single
HTC, and the lack of a control group. The treatment
philosophy and type of ancillary patient support of a
particular HTC may not be possible in all settings. While
there were subjects from CHU Sainte-Justine that were
not on LDDP, this sample was small (8) and not compa-
rable to our LDDP group.Conclusions
In this small cohort of youth and young adults, we
observed that LDDP can be associated with good overall
adherence to treatment, low ABRjoints and ABRall,
stable joint status, and SF-36 scores comparable to those
reported in the literature for severe HA. Furthermore
the relatively low annual consumption of FVIII concen-
trate means that LDDP may reduce the annual factor
concentrate cost per patient. This may be an important
economic consideration in lower-income countries.
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